Studies have shown that active fund managers routinely underperform the S&P500 index*​

Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

IKT Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
229.30%

IKT Stock Analysis

IKT PE Ratio:

IKT PEG Ratio: Not Available

IKT Forward EPS Growth (12 month): 0.00%

IKT PS Ratio:

IKT PSG Ratio: Not Available

IKT Forward Revenue Growth (12 month): 0.00%

IKT Articles

No data was found